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Summary 
This is a prospective Phase I/II study reporting on the outcomes of a novel treatment regimen for 
patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), fit for curative 
treatment but not fit for cisplatin. The treatment regimen was delivered in 92% patients, 4 year DFS 
and OS was 72% and 77%, respectively, there were minimal severe late treatment toxicities. This 
regimen is feasible and warrants further evaluation. 
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 ABSTRACT 
Title:  
Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally 
advanced head and neck squamous cell cancer (LAHNSCC) unfit for cisplatin 
Purpose: 
To report on the outcomes of a novel treatment regimen for patients with LAHNSCC, 
fit for curative treatment but not fit for cisplatin. 
Material and Methods: 
Single arm phase I/II study of previously untreated patients with biopsy proved SCC 
of the oropharynx, larynx or hypopharynx. The primary endpoint was feasibility of the 
regimen – defined as the proportion of patients successfully completing treatment. 
Secondary endpoints were loco-regional control (LRC), failure free survival (FFS), 
overall survival (OS), and treatment toxicities.  
Results: 
Sixty patients. Mean age 66 years (range 42-87 years), 28% of patients were >70 
years. The median follow-up was 4 years. Compliance with treatment was very high: 
feasibility was 55/60 (91.7%, 90% CI [83.3% - 96.7%]) which satisfied the pre-
defined criteria. The 4 year LRC was 82% (95% CI [71 – 94]), FFS was 72% (95% CI 
[60 – 85]) and the OS was 77% (95% CI [66-90]). The cumulative incidences of first 
failure of any type at 4 years were5.2% local, 1.8% local and distant, 8.5% regional, 
1.7% regional and distant, 3.5% distant, and 7.7% death (any cause). The 4 year 
FFS in the 70 years or less and more than 70 years patients were 71% (95% CI [58-
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88]) and 73% (95% CI [54-100]), respectively (logrank p=0.801). Their 4-year OS 
was 79% (95% CI [66-93]) and 73% (95% CI [53-100]), respectively (logrank 
p=0.708). Significant late treatment toxicities were very few. 
 
Conclusion: 
This treatment regimen was feasible and safe in this patient cohort unfit for cisplatin, 
28% of whom were older than 70 years. Carboplatin and cetuximab based 
chemoradiation regimens warrant further investigation in patients with a 
contraindication to cisplatin.  
 
 
 
Introduction 
Concurrent chemoradiotherapy (CRT) is a widespread standard of care for non-
surgical treatment of locally advanced head and neck squamous cell cancer 
(LAHNC). Many individual trials and subsequent meta-analyses have shown that 
concurrent chemotherapy conferred a loco-regional and overall survival benefit 
compared to patients treated with radiotherapy (RT) alone. [1-4] The majority of the 
chemoradiation trials have used cisplatin based regimens. The acute toxicity of these 
regimens is high, and a significant proportion of patients are medically unfit for 
cisplatin (e.g., deafness, borderline cardiac and/or renal function, peripheral 
neuropathy).   
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The optimal chemoradiation regimen for patients medically unfit for cisplatin is 
unclear. One commonly used regimen of proven benefit was reported by GORTEC 
(Groupe d’Oncologie Radiotherapie Tete et Cou). In this study patients were 
randomised to RT alone (70 Gy in 35 fractions) or RT and carboplatin (daily bolus 
70mg/m2 per day for 4 days), and 5-flurouracil (given as a continuous infusion at a 
dose of 600mg/m2 per days for 4 days). The chemotherapy cycle was started on 
days 1, 22, and 43. This phase III study showed improved loco-regional control and 
overall survival for the chemoradiation arm.[3]  
The other common non-cisplatin option in these patients is cetuximab, a monoclonal 
antibody against the epidermal growth factor receptor. The seminal Bonner study of 
the combination of cetuximab with RT showed a significant benefit in loco-regional 
control and overall survival compared to RT alone. [5]  
There has been a mixture of other non-cisplatin based regimens reported. There is 
Australian experience with the “chemoboost regimen”[6]. This regimen included 
patients medically unfit for cisplatin chemotherapy, utilising carboplatin together with 
infusional 5-flurouracil (FU) in the final 2 weeks of a 7-week course of RT (70 Gy in 
35 fractions). We have also previously reported that in a study of postoperative 
chemoradiation for resected head and neck cancer, 20/47 (43%) patients were unfit 
for weekly cisplatin and received weekly carboplatin as an alternative concurrent 
treatment option. [7] There has been one randomized study in which RT alone was 
compared to daily single agent cisplatin or carboplatin, and reported improved local 
control and overall survival in the chemoradiation arms, although the daily 
administration of chemotherapy is burdensome[8].  
The aim of this Phase I/II study was to test the safety and feasibility of a combination 
treatment regimen suitable for patients with LAHNC who were not fit for cisplatin. A 
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common standard of care for such patients is the Bonner regimen, to which we 
added weekly carboplatin , hoping to maintain treatment tolerability and potentially 
enhance treatment efficacy. Weekly carboplatin was chosen as it is generally well 
tolerated in this morefrail population, has been previously utilised in HNC [7,8] and 
does not require the use of central venous catheter devices compared with regimens 
which contain infusional 5-FU.  
The radiotherapy was delivered via the infield boost regimen (IFB), which is similar to 
the concomitant boost RT schedule which showed a major benefit in an unplanned 
subset analysis in the Bonner study.   
Here we report on the outcomes of this prospective treatment regimen that was 
conducted under the auspices of the Trans-Tasman Radiation Oncology Group 
(TROG). 
 
Materials and Methods 
This was a single arm phase I/II trial of previously untreated patients with locally 
advanced (Stage III or IV), biopsy proven SCC of the oropharynx, larynx, or 
hypopharynx, who were fit for curable treatment but unfit for cisplatin chemotherapy. 
The primary endpoint was the feasibility of the regimen in this patient cohort. The 
regimen was considered feasible if it could be safely administered to the study 
population. Hence feasibility was measured by the “completion rate”, which was 
defined as the rate of successfully completing treatment. Completion is defined by 
each of the following 5 criteria being satisfied: 1) at least 94% of the protocol defined 
dose of radiation being administered; 2) at least 4 out of the 6 planned doses of 
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cetuximab with RT being administered (in the Bonner study 90% received all 
planned doses of cetuximab but we did not have any data in combination with 
carboplatin and RT, so the choice of 4/6 (67%) was an estimate bearing in mind that 
experience in Australia had reported more toxicity with the addition of cetuximab [11] 
than reported in the Bonner study); 3) at least 3 of the 5 planned doses of 
carboplatin with RT being administered (prior clinical experience showed 94% 
patients received at least 66% of the planned doses [8]); 4) no incident of life-
threatening (i.e. grade 4) toxicity; and 5) completion of treatment within one week of 
the protocol defined duration of radiation, i.e. within 42 days. The secondary 
objectives were loco-regional control (LRC), failure free survival (FFS), overall 
survival (OS), and treatment toxicities.  
Patients were assessed as medically unfit for cisplatin chemotherapy due to one or 
more of the following reasons: clinically significant sensori-neural hearing impairment 
(audiometric abnormalities without corresponding clinical deafness were not 
regarded as a contraindication to cisplatin), severe tinnitus, renal impairment (GFR < 
60ml/min), > Grade 2 peripheral neuropathy, inability to tolerate intravenous 
hydration e.g. due to cardiac disease, co-morbidities (based on clinical judgement by 
the investigator) associated with ECOG PS 2 that in the view of the investigator 
would preclude the safe administration of cisplatin. They had to have no evidence of 
distant metastatic disease (confirmed by a chest/abdominal computerized 
tomography (CT) or fluorodeoxyglucose (FDG)-Positron Emission Tomography 
(PET)-CT.. Patients had to be at least 18 years of age and have given signed 
consent. 
Statistical analysis 
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Calculation of sample size 
A completion rate of 80% was deemed to be the minimum satisfactory rate. A rate of 
65% would be considered definitely unsatisfactory. The primary endpoint – the 
completion rate – was assessed by its estimate and an exact 90% 2-sided 
confidence interval for the observed rate. The regimen would be considered 
unsuitable if the 90% CI was entirely below 80%, and satisfactory for continued study 
if the 90% CI was entirely above 65%.The sample size was determined such that if 
the true rate is 65%, the 90% CI will be below 80% with at least 80% probability and 
if the true rate is 80%, the 90% CI will be above 65% with at least 80% probability. 
Performing a power analysis using exact methods, it was determined that the 
required sample size to satisfy these conditions was 59 patients. To allow for 
patients who are not fully evaluable, the study aimed to accrue 60 patients. 
The Kaplan-Meier product limit method was used to estimate LRC, FFS and OS. All 
time to event outcomes were measured from the date of registration to the date of 
the event.  Death was a censoring event for LRC. 
Site of first failure was assessed as cumulative incidence of first failure, considering 
each failure separately. Failures were classified as: a) local failure; b) regional 
failure; c) distant failure and; d) death. Cumulative incidence of first failure of any 
type was estimated using competing risk model. 
Worst grade of toxicity was assessed for each patient and described in tabular form. 
As this was a new combination treatment regimen, a Phase I safety component was 
deployed for the first 6 patients. If one or less patient of the first 6 patients had a 
dose limiting toxicity accrual could proceed. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Two subsequent subgroup analyses were introduced, one for p16 positive 
oropharyngeal cancer patients and one for elderly patients (those over 70 years). 
All statistical analyses were performed in R (version 3.1.1). 
Treatment 
Patients were treated with weekly intravenous cetuximab (initial dose of 400mg/m2 in 
the week prior to commencing radiotherapy, then weekly 250mg/m2) and carboplatin 
(AUC 2) weekly for the duration of the radiotherapy. 
The radiotherapy schedule was the IFB regimen - 66 Gy in 35 fractions over 5 
weeks. Phase 1 delivered 50 Gy in 2 Gy daily fractions over 5 weeks, encompassing 
both the gross disease and prophylactic nodal coverage. Phase 2 consisted of a 
second daily fraction of 1.6 Gy, with a minimum 6 hours inter fraction interval, given 
to the gross disease with minimum 5mm margin in the last 10 treatment days. All 
patients were immobilised in a thermoplastic mask and had a planning CT for dose 
calculation. Non conformal, conformal and later intensity modulated radiotherapy 
(IMRT) techniques were allowed.   
Management of the neck 
The protocol dictated that patients who achieved a complete clinical and radiological 
response in the neck at the 3 month assessment would not have a neck dissection.  
Follow-up schedule 
Follow-up visits were at 2, 4, 8, 12 weeks post treatment, then every 3 months for 
the first 2 years, 4 monthly for the third year then 6 monthly until a minimum of 4 
years post treatment. A post treatment CT H&N with intravenous contrast and/ or a 
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PET-CT scan was performed at 12 weeks post treatment, then patients  had aH&N 
CT scan with intravenous contrast every 6 months and annual thyroid function tests. 
Quality Assurance 
All cases had quality assurance review of systemic therapy and all radiotherapy 
contours and dosimetry were reviewed by an independent radiation oncologist.  
Results 
A total of 60 patients were registered between 30/04/2008 and 19/11/2012. Table 1 
shows the distribution of baseline characteristics across the 60 patients. The vast 
majority of patients (86%) were assessed as unfit for cisplatin due to some form of 
hearing impairment. The median age was 66 years, (42-87 years), with 17 patients 
(28%) more than 70 years of age.  Median follow-up was 4 years and all except 4 
patients had at least 2 years of follow-up (minimum protocol follow-up) 
As expected, the majority of patients had oropharyngeal cancer (63%), and of those 
83% were p16 positive.  The majority of patients had a staging PET-CT scan, (56/60, 
93%) in addition to a H&N CT scan with intravenous contrast.  
Compliance with treatment was very high, as shown in Table 2. Overall 58 patients 
(97%) received 5 or more of the planned 6 doses of cetuximab. The 2 patients who 
received less both only had the loading dose of cetuximab, and no carboplatin or 
radiotherapy. One had a Grade 4 hypersensitivity reaction and refused further 
treatment; the other revealed an undiagnosed post-traumatic stress disorder and 
refused further treatment. Three or more cycles of carboplatin was delivered in 57/60 
(95%) patients. All 58 patients who continued treatment received 100% of the 
prescribed RT dose. The radiotherapy technique was conformal in all patients (most 
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commonly the “horseshoe” technique of fixed 6 fields for 50Gy, then opposing off 
spinal cord oblique fields for the remaining 20Gy), but IMRT only in 29 (50%).  
There were only 3 patients (3/58, 5%) with major RT violations: 2 patients (3%) with 
D95 of the PTV66 < 95% (<62.7Gy), and 1 patient whose maximum point dose to 
the mandible was > +7% (>70.6Gy). There were no major protocol violations with 
respect to RT duration nor the inter fraction interval of at least 6hrs. There were no 
major systemic therapy protocol violations. 
As seen in Table 3, the number of patients satisfying all conditions for feasibility was 
55/60 (91.7%, 90% CI [83.3% - 96.7%]) which satisfied the pre-defined feasibility 
criteria. 
The key treatment toxicities are denoted in Table 4. There were no treatment related 
deaths. The grade 3 mucositis and temporary feeding tube requirements were high 
as expected, 90% and 78%, respectively; but none of the patients free of disease 
required ongoing feeding tube nutritional support after 12 months. There were no 
brachial plexus nor spinal cord toxicity. 
The 4 year LRC was 82% (95% CI [71 – 94]), FFS was 72% (95% CI [60 – 85]) and 
the OS was 77% (95% CI [66-90]). The cumulative incidences of first failure of any 
type at 4 years were 5.2% local, 1.8% local and distant, 8.5% regional, 1.7% regional 
and distant, 3.5% distant, and 7.7% death (any cause).   
The 4 year FFS for the p16 positive and p16 negative OPC patients were 80% (95% 
CI [65 – 98]) and 50% (95% CI [22-100]), respectively (logrank p=0.117). The 4 year 
OS the p16 positive and negative groups were 93% (95% CI [84 -100]) and 50% 
(95% CI [22-100]), respectively (logrank p=0.031). 
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The disease characteristics of the 2 age cohorts are shown in Table 5. Compliance 
with treatment was high in both groups - 93% in patients 70 years or less and 88% in 
patients more than 70 years. The 4 year FFS in the 70 years or less and more than 
70 years patients were 71% (95% CI [58-88]) and 73% (95% CI [54-100]), 
respectively (logrank p=0.801).  See Figure 1.Their 4-year OS was 79% (95% CI [66-
93]) and 73% (95% CI [53-100]), respectively (logrank p=0.708). 
  
Discussion 
This regimen proved to be safe and feasible in the population of LAHNSCC patients 
not fit for cisplatin. Treatment toxicities were significant, as one expects with radical 
HN treatment, but manageable with no treatment related deaths. 
Although only 50% patients were treated entirely with intensity modulated 
radiotherapy (IMRT), the late toxicities were minimal. In particular, there were no 
patients alive with no evidence of disease who required ongoing feeding tube 
nutritional support, no brachial plexus injuries, no spinal cord injuries and only 2 
cases (3%) of osteoradionecrosis – which included one patient with exposed 
mandible that healed with observation. 
Clarifying what is the optimal CRT treatment regimen in patients who are not fit for 
cisplatin is of clinical importance, particularly as the aging population continues to 
grow. In the current study, the mean patient age was 66 years, and 28% of patients 
were more than 70 years. We didn’t find a difference in FFS or OS in the more 
elderly cohort. Compliance with treatment was high in all patients, including those 
more than 70 years. 
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We know from the RTOG 0522 study (8) that concurrent cetuximab adds no 
additional benefit to concurrent cisplatin. The role of concurrent cetuximab in 
comparison to concurrent cisplatin is currently uncertain. A recently published 
prospective randomised study by Magrini et al, comparing weekly cetuximab with 
weekly cisplatin in LAHNC raised concerns about the efficacy and toxicity of 
concurrent cetuximab in comparison to concurrent cisplatin. This study closed 
accrual early (70 patients of a planned 130) and so was underpowered to show a 
statistically significant difference in outcomes[10]. It has not been until the 
emergence of human papilloma virus (HPV) related oropharyngeal cancer era that 
studies have been activated directly comparing concurrent cetuximab versus 
concurrent cisplatin, and the results of these studies are eagerly awaited (RTOG 
1016 NCT01302834;TROG 12.01 NCT01855451;DeESCALaTE NCT01874171). 
Nevertheless, they will not be directly relevant to optimisation of treatment regimens 
for patients unfit for cisplatin.   
Fortunately, the high acute toxicities and mortality (19%) rates in the cetuximab arm 
of the Magrini et al study are not the usual experience in the clinical use of 
cetuximab, and certainly weren’t our experience in this current study. Even allowing 
for the fact that the Bonner study [5] may have underestimated the acute toxicities of 
concurrent cetuximab, particularly the claim of no increased acute skin toxicities [11] 
, other studies [9, 12] have not shown anything near the severe hypersensitivity 
reactions, prolonged treatment interruptions and cetuximab treatment related deaths 
reported in the Magrini study.   
Our original plan, if this regimen was found to be tolerable, was to compare it in a 
randomised study to the GORTEC regimen for patients unfit for cisplatin. Since that 
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time there has been reported experience with other regimens that would also be 
suitable for patients not fit for cisplatin.  
One of these is concurrent weekly paclitaxel and carboplatin in the treatment of 
LAHNC. The doses have varied slightly (weekly paclitaxel dose ranging from 30mg, 
40 or 45mg/m2; and the weekly carboplatin dose from AUC1, AUC1.5 or 100mg/m2). 
This chemotherapy doublet has been combined with the concomitant boost 
radiotherapy regimen [13, 14] and with IMRT [15]. The 3 year LRC rates were very 
good (72%, 83%, 95%, respectively) and the acute toxicities were high but 
manageable. It’s worth noting that the patients in these studies were younger (mean 
age 58 years) than our study mean age of 66 years. 
GORTEC have presented in preliminary form the results of 2007-01 in which 406 
patients (fit for chemotherapy but not necessarily unfit for cisplatin), were 
randomized to 70Gy over 7 weeks with concurrent cetuximab or concurrent 
carboplatin, 5FU (as per Calais 1999, [3]) and cetuximab as definitive treatment in 
LAHNSCC. They showed significantly better loco-regional control and progression 
free survival in the carboplatin, 5FU and cetuximab arm compared to cetuximab 
alone, but the difference in overall survival was not statistically significant. These 
results raise doubts about the adequacy of cetuximab and RT, but it remains unclear 
whether carboplatin,5FU and cetuximab with RT is superior to the same regimen 
without the cetuximab.  Furthermore, these 2 regimens have not been specifically 
tested in patients unfit for cisplatin.   Moving forward, in patients unfit for cisplatin, it 
would be clinically useful to compare in a randomised manner our concurrent 
regimen with that of concurrent carboplatin, 5FU +/- cetuximab, and the concurrent 
carboplatin/paclitaxel doublet.   
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Conclusion 
This treatment regimen was feasible and safe in this patient cohort unfit for cisplatin, 
28% of whom were greater than 70 years. Carboplatin and cetuximab based 
chemoradiation regimens warrant further evaluation in patients with a 
contraindication(s) to cisplatin.  
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Table 1: Patient characteristics 
Variable n (%) 
Reason medically unfit for cisplatin 
       co-morbidities associated with ECOG PS 2 3 (5%) 
       inability to tolerate intravenous hydration 3 (5%) 
       renal impairment 3 (5%) 
       sensori-neural hearing impairment 34 (57%) 
       sensori-neural hearing impairment + renal impairment 1 (2%) 
       sensori-neural hearing impairment + severe tinnitus 6 (10%) 
       severe tinnitus 10 (17%) 
Primary site 
       Hypopharynx 6 (10%) 
       Larynx 16 (27%) 
       Oropharynx 38 (63%) 
p16 status (oropharynx patients only)  
       Negative         6 (17%) 
       Positive 29 (83%) 
       No tumour          3 
Age at Registration (grouped) 
       ≤ 70 years 43 (72%) 
       > 70 years 17 (28%) 
Gender 
       Female 3 (5%) 
       Male 57 (95%) 
ECOG 
       0 37 (62%) 
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       1 21 (35%) 
       2 2 (3%) 
T stage 
       1 3 (5%) 
       2 24 (40%) 
       3 26 (43%) 
       4a 7 (12%) 
N stage 
       0 12 (20%) 
       1 7 (12%) 
       2a 5 (8%) 
       2b 21 (35%) 
       2c 12 (20%) 
       3 3 (5%) 
Stage 
       III 14 (23%) 
       IV 46 (77%) 
 
Table 2: Systemic therapy received 
 
Variable statistic n (%) 
Planned first carboplatin dose 
Mean (SD) 227 (53) 
Median [range] 225 [133 - 368] 
Interquartile range 180 – 266 
Cetuximab doses given  
(≥80% of prescribed dose) 
1 2 (3%) 
5 10 (17%) 
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6 48 (80%) 
Carboplatin doses given 
(≥80% of prescribed dose) 
0 2 (3%) 
1 1 (2%) 
3 1 (2%) 
4 10 (17%) 
5 46 (77%) 
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Table 3: Satisfaction rate for each of the conditions necessary for feasibility of the 
primary objective, considered collectively. 
 
≥ 94% 
RT dose 
≥ 4 cetuximab 
doses 
≥ 3 carboplatin 
doses 
No grade 4 
toxicity 
RT duration 
≤ 42 days 
Overall 
Feasibility n 
FALSE FALSE FALSE TRUE FALSE FALSE 2 
TRUE TRUE TRUE FALSE TRUE FALSE 2 
TRUE TRUE FALSE TRUE TRUE FALSE 1 
TRUE TRUE TRUE TRUE TRUE TRUE 55  
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Table 4:  *CTCAE v 3 Treatment toxicities. Number of patients experiencing the 
toxicity out of 58 patients. 
Adverse event Grade 2 Grade 3 Grade 4 
Anaphylaxis 
  
1 (2%)¥ 
Haemorrhage (GI)£ 
  
1 (2%) 
Non neutropenic sepsis  
 
6 (10%)  1 (2%) 
Mucositis  5 (9%) 52 (90%) 
Feeding tube (NGT/PEG) 
 
45 (78%) 
Radiation dermatitis  28 (48%) 20 (35%) 
 
Acne skin reaction  36 (62%) 9 (16%) 
 
Dry mouth 42 (72%) 6 (10%)  
 
Nausea 10 (17%) 4 (7%) 
 
Vomiting  6 (10%) 2 (3%) 
 Infection with unknown ANC (Bronchus) 
 
1 (2%) 
Febrile neutropenia 
 
1 (2%) 
 
Hearing loss 
 
1 (2%) 
 Osteoradionecrosis 2 (3%) 
 Hypothyroidism 3 (5%) 
 Soft tissue Fibrosis 14 (24%) 
 
 Dysphagia > 12 months 15 (26%) 
 
 
¥
 Not part of the 58 patients. This was one of the two patients who ceased treatment early. 
*CTCAE version 3 (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf) 
£
 Unrelated to treatment 
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Table 5: Disease characteristics of the 2 age cohorts. 
Variable Age ≤ 70 Age > 70 
Primary site 
 
 
       Hypopharynx 2 (5%) 4 (24%) 
       Larynx 9 (21%) 7 (41%) 
       Oropharynx 32 (74%) 6 (35%) 
T stage 
 
 
       1 3 (7%) 0 (0%) 
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       2 20 (47%) 4 (24%) 
       3 17 (40%) 9 (53%) 
       4a 3 (7%) 4 (24%) 
N stage 
 
 
       0 6 (14%) 6 (35%) 
       1 5 (12%) 2 (12%) 
       2a 5 (12%) 0 (0%) 
       2b 19 (44%) 2 (12%) 
       2c 6 (14%) 6 (35%) 
       3 2 (5%) 1 (6%) 
Stage 
 
 
       III 9 (21%) 5 (29%) 
       IV 34 (79%) 12 (71%) 
p16 status  (oropharynx patients only) 
 
 
       Negative 5 (17%) 1 (17%) 
       Positive 24 (83%) 5 (83%) 
       No tumour 3 0 
       Missing 0 0 
Treatment feasible 
 
 
       No 3 (7%) 2 (12%) 
       Yes 40 (93%) 15 (88%) 
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